Rick Lifsitz Named Principal Consultant at Scientia Advisors

Medical device and healthcare informatics expert to help health, diagnostics, biotech, device and pharma companies determine best strategies for growth

BOSTON--(BUSINESS WIRE)-- Scientia Advisors, a leading healthcare consulting firm specializing in growth strategies for companies in healthcare, life sciences, biotechnology, and nutrition and wellness, today announced that Richard Lifsitz has joined the firm as a Principal.

Lifsitz is one of the leading experts in medical devices/diagnostics and information technology. He will help Scientia Advisors clients successfully develop strategies to meet the challenges they face from competition and new product innovation and business models, while taking advantage of the explosion in data that is creating new opportunities across the healthcare continuum.

“Rick is one of the leading experts in applying technology and new business models to build high-growth and innovative healthcare companies. He has a proven track record in leading healthcare and life science companies to profitability,” said Harry Glorikian, Scientia Advisors managing partner. “His knowledge, skill, and business acumen will be invaluable to healthcare, diagnostics, device, biotechnology and pharmaceutical companies of all sizes and stages. We are delighted that he has joined our firm. ”

Lifsitz comes to Scientia Advisors with more than 25 years of successful operating and consulting experience in start-up, midmarket and Fortune 500 health care and technology companies.

Most recently, Lifsitz was Chief Operating Officer of HyperMed, a venture-backed hyperspectral imaging company focused on improving diagnosis and therapy for patients with critical limb ischemia and diabetic foot ulcers. Lifsitz also served as the Vice President of Product Management and Business Development at AMICAS, the first Web-based Picture and Archiving Communications System (PACS). The Company was sold to Merge Healthcare in 2010.

Previously, he had founded and led a variety of highly successful, venture-backed, Internet and information technology firms.

Mr. Lifsitz, who holds a BA from the University of Michigan and an MBA from the Harvard Business School, has also worked at the Boston Consulting Group , where he focused on corporate strategy and re-engineering assignments for numerous Fortune 500 clients. Very early in his career, he held positions at Procter and Gamble and the world’s largest mini-computer manufacturer.

Lifsitz said, “Scientia Advisors is unique in helping companies in the healthcare industry develop competitive strategies, from the boardroom to the bench level. I’m excited to work with a team that understands the business of science, and helps clients develop and leverage innovation in medical devices, diagnostics, informatics and other technologies to achieve higher levels of growth and competitiveness.”

About Scientia Advisors

Scientia Advisors is a growth strategy firm for the healthcare market. Scientia Advisors works closely with senior management to develop corporate, division, and product strategies that leverage market opportunities and successfully navigate the rapidly evolving healthcare marketplace. Firms across the healthcare value chain rely on Scientia Advisors to help make the right decisions. Today, healthcare growth strategies from Scientia Advisors are propelling firms in pharma, biotech, medtech, IVD, nutrition and wellness, chemical, as well as consumer electronics and telecom. For more information, visit www.scientiaadv.com.



CONTACT:

Scientia Advisors, LLC
Meghan Needham, 617-299-3003
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Fitness & Nutrition  Medical Devices  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.